Vo Nam Xuan, Le Ngan Nguyen Hoang, Chu Trinh Dang Phuong, Pham Huong Lai, Dinh Khang Xuan An, Che Uyen Thi Thuc, Ngo Thanh Thi Thanh, Bui Tien Thuy
Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
Faculty of Pharmacy, Le Van Thinh Hospital, Ho Chi Minh City 700000, Vietnam.
Healthcare (Basel). 2023 Aug 18;11(16):2340. doi: 10.3390/healthcare11162340.
Osteoarthritis (OA) is a chronic condition that most frequently affects older adults. It is currently the most common disability. The cost of treating an aging population places pressure on the healthcare budget. As a result, it is imperative to evaluate medicines' cost-effectiveness and, accordingly, their influence on health resource allocation. Our study aims to summarize the cost and outcome of utilizing glucosamine in OA treatment. Databases like Medline, Cochrane, and Scopus were searched as part of the identification process up until April 2023. Our primary inclusion criteria centered on the economic evaluation of glucosamine in OA treatments, providing an incremental cost-effectiveness ratio (ICER). The Quality of Health Economic Studies (QHES) instrument was applied to grade the quality of the studies. Seven qualified studies that discussed the cost-effectiveness of glucosamine with or without other formulations were selected. All of them demonstrated that glucosamine was cost-effective. There was an increase in quality-adjusted life years (QALYs) when incorporating glucosamine in conventional care. Moreover, patented crystalline glucosamine sulfate (pCGS) was more cost-effective than the other formulations of glucosamine (OFG). Overall, utilizing pCGS was more beneficial than using OFG in terms both of cost and quality of life.
骨关节炎（OA）是一种最常影响老年人的慢性疾病。它是目前最常见的致残原因。治疗老龄化人口的成本给医疗保健预算带来了压力。因此，评估药物的成本效益以及它们对卫生资源分配的影响势在必行。我们的研究旨在总结使用氨基葡萄糖治疗骨关节炎的成本和结果。作为识别过程的一部分，检索了Medline、Cochrane和Scopus等数据库，直至2023年4月。我们的主要纳入标准集中在氨基葡萄糖治疗骨关节炎的经济评估上，提供增量成本效益比（ICER）。应用健康经济研究质量（QHES）工具对研究质量进行分级。选择了七项讨论了氨基葡萄糖与其他制剂联合或不联合使用的成本效益的合格研究。所有研究都表明氨基葡萄糖具有成本效益。在传统治疗中加入氨基葡萄糖后，质量调整生命年（QALY）有所增加。此外，专利结晶硫酸氨基葡萄糖（pCGS）比其他氨基葡萄糖制剂（OFG）更具成本效益。总体而言，在成本和生活质量方面，使用pCGS比使用OFG更有益。
